Recent advances have led to the appreciation that Pathogen-associated Molecular Patterns (PAMPs) derived from microbial pathogens have adjuvant activities. A major conceptual advance in innate immunity has been the discovery of Pattern Recognition Receptors (PRR) that recognize these PAMPs. This recognition profoundly shapes adaptive immunity, thereby impacting host responses to pathogens and to vaccines. A plethora of PRR families have now been described. While some PAMPs are known to activate a specific receptor, more in-depth analyses have revealed that many PAMPs activate multiple PRRs or PRR pathways. The overarching purpose of this project is to use a novel nanoparticle (NP) platform to deliver PAMPs that can best activate the innate immune system to shape the desirable adaptive immunity for beneficial, efficacious vaccine outcome. The distinguishing technology platform of this application is the production of NP by a soft lithography particle molding process called Particle Replication In Nonwetting Templates (PRINT), a technology described and further studied in Project 1. A major advantage of PRINT is the fabrication of large quantities of immunologically-inert NPs of precise size, chemistry, porosity and shape of Good Manufacturing Practices (GMP) quality. This proposal plans to co-deliver antigen and PAM adjuvant complexes by PRINT-NP to optimize vaccine responses. This platform of vaccine/adjuvant delivery by NP will be used to test vaccines against viral pathogens of high medical needs. Mechanistic studies are also proposed to understand how the PAMP adjuvants activate the immune system by defining the specific receptors that mediate the effect of a PAMP adjuvant(s). Challenge studies will be performed in appropriate large or larger animal models to enable eventual translation to the clinic.

Public Health Relevance

The overarching purpose of this project is to use nanoparticles (NP) to deliver PAMP adjuvants that activate the innate immune system through a nano-technology platform that is both precise in formulation and uniform in biologic properties. We will focus on vaccines for high medical need viral infections, which are of broad importance in public health. The end goal is to achieve a novel product vaccine platform.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Metz, Stefan W; Gallichotte, Emily N; Brackbill, Alex et al. (2017) In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers. Sci Rep 7:4524
Junkins, Robert D; Gallovic, Matthew D; Johnson, Brandon M et al. (2017) A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release 270:1-13
Cheng, Liang; Zhang, Zheng; Li, Guangming et al. (2017) Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system. Vaccine 35:6143-6153
Kai, Marc P; Brighton, Hailey E; Fromen, Catherine A et al. (2016) Tumor Presence Induces Global Immune Changes and Enhances Nanoparticle Clearance. ACS Nano 10:861-70
DeSimone, Joseph M (2016) Co-opting Moore's law: Therapeutics, vaccines and interfacially active particles manufactured via PRINT®. J Control Release 240:541-543
Metz, Stefan W; Tian, Shaomin; Hoekstra, Gabriel et al. (2016) Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses. PLoS Negl Trop Dis 10:e0005071
Fromen, Catherine A; Rahhal, Tojan B; Robbins, Gregory R et al. (2016) Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells. Nanomedicine 12:677-687
Callaway, Justin B; Smith, Scott A; Widman, Douglas G et al. (2015) Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1? Secretion: A Primary Human Monocyte Model. PLoS One 10:e0136708
Callaway, Justin B; Smith, Scott A; McKinnon, Karen P et al. (2015) Spleen Tyrosine Kinase (Syk) Mediates IL-1? Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection. J Biol Chem 290:17306-20
Robbins, Gregory R; Roberts, Reid A; Guo, Haitao et al. (2015) Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model. Nanomedicine 11:589-99

Showing the most recent 10 out of 14 publications